Xbrane Biopharma AB (publ) (STO:XBRANE)

Sweden · Delayed Price · Currency is SEK

6.12

-0.13 (-2.14%)

Feb 26, 2026, 5:29 PM CET

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Biosimilar Development		198.72M	238.73M	57.62M	10.71M			-
Biosimilar Development Growth		-16.76%	314.33%	438.03%	-			-
Long-Acting Injectable Drugs		-	-	-	-			20.49M
Long-Acting Injectable Drugs Growth		-	-	-	-			-1.38%
Total		198.72M	238.73M	57.62M	10.71M			20.49M
Total Growth		-16.76%	314.33%	438.03%	-			-1.38%

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
North America		77.00M	28.70M	-	-			-
North America Growth		168.29%	-	-	-			-
Germany		66.50M	209.90M	-	-			-
Germany Growth		-68.32%	-	-	-			-
India		54.10M	-	-	-			-
Middle East		-	-	-	-			20.49M
Middle East Growth		-	-	-	-			-1.38%
Total		197.60M	238.60M	-	-			20.49M
Total Growth		-17.18%	-	-	-			-1.38%

Source: S&P Global Market Intelligence.